Solutions for Life Science & Diagnostics
Anti-PI-9 (Proteinase Inhibitor 9) (Human) mAb
Additional Information
Anti-PI-9 (Proteinase Inhibitor 9) (Human) mAb Specifications
| Background: | Cytotoxic T lymphocytes (CTL) mediate the induction of an anti-tumor effect. CTLs lyse their targets by means of two distinct mechanisms involving granule exocytosis and the cross-linking of so-called death receptors on the target cell. Granzyme B (GrB) is contained in the granules and released to tumors when CTL is primed by antigen presenting cells such as dendritic cells. After GrB enters the tumors, many proteins including Bid, inhibitor of caspase-activated DNase (ICAD), and caspases-3, -7, and -8 are cleaved by GrB, resulting in the induction of apoptosis in the tumors. In several cases, tumors acquire immune escape mechanisms from tumor-specific CTLs in vivo. Recent evidence indicates that protease inhibitor (PI)-9, a serine protease inhibitor (serpin), can efficiently and irreversibly inactivate GrB in vitro. It is reported that expression of PI-9 is observed in a subset of human melanomas as well as in human breast, cervical, and colon carcinomas. |
| Clonality: | Monoclonal |
| Clone Number: | 7D8 |
| Formulation: | 1 mg/mL in PBS/50% glycerol, pH 7.2 |
| Gene ID Human: | 5272 |
| Gene ID Mouse: | 20723 |
| Host Species: | Mouse |
| Immunogen: | Recombinant Human PI-9 |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
| Isotype: | IgG1 |
| Product Type: | Primary Antibody |
| Shipping: | 4 |
| Size: | 100 μg |
| Species Reactivities: | Human |
| Status: | RUO |
| Storage: | -20℃ |
| Target: | PI-9 |
Applications: FCM, IH, IP, WB
| FCM: | 1-5 μg/mL (final concentration) |
| IHC: | 10 μg/mL (Heat treatment is necessary for paraffin |
| IPP: | 2 μg/200 μL of cell extract from 5x106 |
| WB: | 1 μg/mL |
There are no references for Anti-PI-9 (Proteinase Inhibitor 9) (Human) mAb at this time.
Product Images
